We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The European Medicines Agency's (EMEA) management board has issued a release addressing a rise in applications for medicines in 2006 and concerns over budget situation for next year.
York Pharma PLC said the launch date of its lead product Abaso -- a cream for treating fungal skin infections -- has been delayed to the first half of next year after a UK regulator asked for further data on the product.
SIGA Technologies, Inc. disclosed that it had terminated its Agreement and Plan of Merger with PharmAthene, Inc., pursuant to the terms of that agreement.
UK pharmaceutical companies are not doing enough to attract fresh talent to the industry and face serious future recruitment issues if they don't get their act together now, warns a new report.
FACTIVE (gemifloxacin mesylate) tablets, Oscient Pharmaceuticals Corporation's lead antibiotic product, has been launched by Pfizer, S.A. de C.V. (Pfizer Mexico), the largest pharmaceutical company in Mexico.
The Global Fund to Fight AIDS, Tuberculosis and Malaria has announced that a review panel has recommended 85 requests for funding worth a total of $949 million over two years to the board of the Global Fund for its consideration.